Article Text

Download PDFPDF

338 Emerging insights on the association of tumor molecular phenotype with clinical benefit in metastatic colorectal cancer (mCRC) subjects treated with AB928 + modified FOLFOX-6 (mFOLFOX-6)
  1. Akshata Udyavar1,
  2. Michael Cecchini2,
  3. Daniel DiRenzo1,
  4. Sean Cho1,
  5. Lisa Seitz1,
  6. Kristen Zhang1,
  7. Stephen Young1,
  8. Amy Anderson1,
  9. Kimberline Gerrick1,
  10. Matthew Walters1,
  11. Houston Gilbert1,
  12. Olivia Gardner1,
  13. Cheng Quah1,
  14. Juan Jaen1 and
  15. William Grossman1
  1. 1Arcus Biosciences Inc, Hayward, CA, USA
  2. 2Yale University, New Haven, CT, USA


Background The release of ATP from dying cancer cells in response to platinum-based chemotherapy increases extracellular adenosine, which binds to and activates A2aR and A2bR receptors to generate an immunosuppressive microenvironment. This is mediated by the activation of A2aR on intra-tumoral T and NK cells, A2aR and A2bR on tumor-infiltrating myeloid cells, and A2bR on cancer cells.1 Importantly, expression of A2bR and CD73, an adenosine-producing enzyme, on cancer cells is upregulated by oncogenic drivers such as KRAS.2 Consistent with this, tumors from CRC subjects express high levels of A2bR. Adenosine receptor blockade may therefore enhance the therapeutic efficacy of certain chemotherapeutic agents. AB928 is the first clinical-stage small-molecule dual adenosine receptor antagonist, targeting both A2aR and A2bR. The preliminary safety and clinical efficacy of AB928 + mFOLFOX-6 in metastatic colorectal cancer (ARC-3; NCT03720678) were recently described.3 This presentation describes the preliminary identification of molecular markers that correlate with the extent of clinical benefit in this trial.

Methods A total of 35 subjects enrolled in this study: 12 (1L); 4 (2L); and 19 (3L+). Baseline and on-treatment biopsy samples were subjected to immunofluorescent staining as well as WES and RNAseq analysis.

Results Analysis of the primary CRC dataset in TCGA highlights this tumor type as having high levels of CD73, coupled with a paucity of Tissue Nonspecific Alkaline Phosphatase (TNAP), another enzyme that can produce adenosine. In our mCRC study samples, TNAP was often present, being expressed on either stroma or tumor and in a non-overlapping manner with CD73. Analysis of the expression levels of these enzymes and other proteins involved in the adenosine axis (e.g., A2bR) revealed trends that could have predictive value, particularly in late-line subjects. Correlative trends were also observed between the infiltration of lymphocytes within baseline tumor samples and the extent of clinical benefit. Based on a preliminary and ongoing analysis of baseline biopsies, a number of molecular markers may correlate with better clinical outcomes, most relevantly in late-line mCRC subjects treated with AB928 + mFOLFOX-6. These data suggest the possibility that adenosine-related markers may be helpful in future studies for selection of patients to be treated with AB928 + mFOLFOX-6 therapy.

Conclusions N/A

Acknowledgements N/A

Trial Registration NCT03720678

Ethics Approval The study was approved by all the study site Institution’s Ethics Boards, with Advarra IRB being the first, approval number SSU00070639 in USA.

Consent N/A


  1. Vijayan D, et al. Nat Rev Cancer. 2017;17(12):765

  2. Udyavar A, AACR Annual Meeting 2019.

  3. Cecchini M, AACR Annual Meeting 2020.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.